Humacyte, Inc.
HUMA
Rank in Stocks
#17488
Humacyte, Inc. focuses on developing and manufacturing readily available,... Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Share Price
$0.5954
Last synced: 2026-11-12
Market Cap
$165.40M
Change (1 day)
0.63%
Change (1 year)
-51.59%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Humacyte, Inc. (HUMA)
Category
Healthcare
Earnings for Humacyte, Inc. (HUMA)
Earnings in Jun 2026 TTM: $-96.74M
According to Humacyte, Inc.'s latest financial reports, its current earnings (TTM) are $-96.74M. In 2025 the company earned $-40.83M, an increase over its 2024 earnings of $-148.70M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Humacyte, Inc. from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-96.74M | 136.90% |
| 2025 | $-40.83M | -72.54% |
| 2024 | $-148.70M | 34.24% |
| 2023 | $-110.78M | 825.83% |
| 2022 | $-11.97M | -54.81% |
| 2021 | $-26.48M | -60.20% |
| 2020 | $-66.52M | -22.12% |
| 2019 | $-85.42M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $-59.03M | -38.98% |
US
|
|
| $4.76B | -5,020.14% |
US
|
|
| $-2.73B | 2,721.11% |
US
|
|
| $-4.02B | 4,051.75% |
AU
|
|
| $2.83B | -3,021.20% |
BE
|
Questions about Humacyte, Inc.'s net income
What is Humacyte, Inc.'s net income?
Humacyte, Inc.'s net income over the last twelve months is $-96.74M, as of Jun 2026.
What was Humacyte, Inc.'s net income in 2025?
In 2025, Humacyte, Inc.'s net income was $-40.83M, compared with $-148.70M in 2024.
How has Humacyte, Inc.'s net income changed since 2020?
From 2020 to 2025, Humacyte, Inc.'s net income was highest in 2022 ($-11.97M) and lowest in 2024 ($-148.70M).
How does Humacyte, Inc.'s net income compare with similar companies?
Humacyte, Inc.'s net income ($-96.74M) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $4.76B.